In summary, this study identified CYP1B1 and TNFAIP6 as potential molecular targets for IDD that warrant further validation and developed a nomogram with potential clinical utility, which also requires additional confirmation. This evidence concerns the gene CYP1B1 and intervertebral disk degenerative disorder.